The Technical Analyst
Travere Therapeutics, [TVTX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Travere Therapeutics, Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-2.20% $5.33
America/New_York / 25 apr 2024 @ 13:33
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 405.61 mill |
| EPS: | -5.07 |
| P/E: | -1.050 |
| Earnings Date: | May 02, 2024 |
| SharesOutstanding: | 76.10 mill |
| Avg Daily Volume: | 1.203 mill |
| RATING 2024-04-25 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.050 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.18x |
| Company: PE -1.050 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 4.83 - 5.79 ( +/- 9.02%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-11 | Cline Christopher R. | Sell | 54 | Common Stock |
| 2024-01-31 | Dube Eric M | Buy | 135 000 | Common Stock |
| 2024-02-01 | Dube Eric M | Sell | 9 106 | Common Stock |
| 2024-01-31 | Dube Eric M | Buy | 360 000 | Employee stock option (right to buy) |
| 2024-02-01 | Dube Eric M | Sell | 10 016 | Common Stock |
| INSIDER POWER |
|---|
| 89.26 |
| Last 100 transactions |
| Buy: 2 015 500 | Sell: 106 721 |
Forecast:
15:12 - $5.31
Live Trading Signals (every 1 min)
Forecast
1: 13:42 - $5.33
Forecast 2: 14:32 - $5.32
Forecast 3: 15:12 - $5.31
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $5.33 (-2.20% ) |
| Volume | 0.698 mill |
| Avg. Vol. | 1.203 mill |
| % of Avg. Vol | 58.02 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For TVTX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:33 | sell | $8.33 | N/A | Active |
|---|
TVTX
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Latest Press Releases
2024-04-24 07:05:00 - Press Release
Travere Therapeutics And Csl Vifor Announce European Commission Approves Filspari® (sparsentan) For The Treatment Of Iga Nephropathy
Travere and csl vifor announce ec approval of filspari (sparsentan) for treatment of igan, 1st non-immunosuppressive treatment for igan approved in europe
2024-04-24 03:00:00 - Press Release
Csl Vifor And Travere Therapeutics Announce European Commission Approves Filspari® (sparsentan) For The Treatment Of Iga Nephropathy
First non-immunosuppressive therapy for the treatment of iga nephropathy (igan) approved in europe conditional marketing authorization is based on statistically significant and clinically meaningful results from the phase-iii protect trial st. gallen, switzerland and san diego, april 24, 2024 /prnewswire/ -- csl vifor and travere therapeutics, inc., (nasdaq: tvtx) today announced that the european commission has granted conditional marketing authorization (cma) for filspari (sparsentan) for the treatment of adults with primary igan with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g).
2024-04-04 16:30:00 - Press Release
Travere Therapeutics To Present Abstracts At The Society For Inherited Metabolic Disorders And Genetic Metabolic Dieticians International
Travere to present abstracts at simd and gmdi highlighting research investigating pegtibatinase as the first potential disease-modifying therapy for hcu
2024-04-03 16:30:00 - Press Release
Travere Therapeutics To Present Abstracts On Filspari® (sparsentan) In Iga Nephropathy At World Congress Of Nephrology And The American Nephrology Nurses Association
San diego, april 03, 2024 (globe newswire) -- travere therapeutics, inc., (nasdaq: tvtx) today announced that the company will present nine abstracts in rare kidney disease at the world congress of nephrology (wcn) in buenos aires, argentina, on april 13-16, 2024, and the american nephrology nurses association (anna) national symposium in orlando, florida, on april 14-17, 2024. at wcn, the company will present subgroup analyses of the phase 3 protect study of filspari® (sparsentan) in iga nephropathy (igan) showing the treatment effect across participants with different levels of baseline proteinuria.
2024-03-13 17:00:00 - Press Release
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
San diego, march 13, 2024 (globe newswire) -- travere therapeutics, inc. (nasdaq: tvtx) today announced that on march 10, 2024, the compensation committee of its board of directors granted inducement equity grants covering an aggregate of 51,600 shares of its common stock to four new employees, consisting of inducement stock options to purchase an aggregate of 25,000 shares of common stock and inducement restricted stock units, or rsus, covering an aggregate of 26,600 shares of its common stock. these inducement stock options and inducement rsus are subject to the terms of travere's 2018 equity incentive plan (“2018 plan”), but were granted outside of the 2018 plan and were granted as inducements material to the new employees entering into employment with travere in accordance with nasdaq listing rule 5635(c)(4).
Latest News
2024-04-04 16:30:00 - GlobeNewsWire
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International
Travere to present abstracts at SIMD and GMDI highlighting research investigating pegtibatinase as the first potential disease-modifying therapy for HCU
2024-04-03 16:30:00 - GlobeNewsWire
Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present nine abstracts in rare kidney disease at the World Congress of Nephrology (WCN) in Buenos Aires, Argentina, on April 13-16, 2024, and the American Nephrology Nurses Association (ANNA) National Symposium in Orlando, Florida, on April 14-17, 2024. At WCN, the Company will present subgroup analyses of the Phase 3 PROTECT Study of FILSPARI® (sparsentan) in IgA nephropathy (IgAN) showing the treatment effect across participants with different levels of baseline proteinuria.
2024-02-26 16:30:00 - GlobeNewsWire
Travere Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will participate in the following upcoming investor conferences in March:
2024-02-16 05:05:19 - Seeking Alpha
Travere Therapeutics, Inc. (TVTX) Q4 2023 Earnings Call Transcript
2024-02-15 18:31:10 - Zacks Investment Research
Travere (TVTX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Travere (TVTX) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
2024-02-08 16:30:00 - GlobeNewsWire
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
SAN DIEGO, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2023 financial results on Thursday, February 15, 2024, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.
2024-02-01 16:30:00 - GlobeNewsWire
Travere Therapeutics to Present at the Guggenheim 6th Annual Biotechnology Conference
SAN DIEGO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will present at the Guggenheim 6th Annual Biotechnology Conference on Thursday, February 8, 2024, at 11:30 a.m. ET.
2024-01-24 12:26:03 - Zacks Investment Research
Travere (TVTX) Stock Up More Than 30% in 3 Months: Here's Why
Travere (TVTX) is on track to file an sNDA to the FDA to convert the accelerated approval for lead drug, Filspari, to full approval for IgAN in first-quarter 2024.
2024-01-02 16:30:00 - GlobeNewsWire
Travere Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Eric Dube, Ph.D., president and chief executive officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 3:45 p.m. PT.
2023-12-06 13:32:07 - Zacks Investment Research
Travere (TVTX) Up on Latest Portfolio Updates & Reorganization
Travere (TVTX) to submit an sNDA to the FDA to convert the accelerated approval for Filspari to full approval for IgAN in first-quarter 2024. The company is implementing a strategic reorganization to cut costs.